Epic Sciences has recieved accreditation from the College of American Pathologists (CAP). The CAP Laboratory Accreditation Program is recognized by the United States government as being equally or more stringent than the federal inspection program and is designed to specifically ensure the highest standard of care for all laboratory samples.
“Our investment in a high-throughput, CLIA/CAP laboratory will give drug developers and academic investigators alike the ability to scale Epic Sciences’ circulating tumor cell (CTC) based liquid biopsy tests from small observational studies to large Phase III trials,” said Murali Prahalad, Ph.D., President and CEO of Epic Sciences.
Epic Sciences has analyzed more than 10,000 blood samples from cancer patients and is in use in more than 58 active clinical trials. The identification and characterization of CTCs from a liquid biopsy, allows for the development of companion diagnostics that match the right patients to the right therapies at the right time.